PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
47.13%
Net income growth above 1.5x TRVN's 7.84%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
3.87%
Some D&A expansion while TRVN is negative at -2.38%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
17.23%
Some yoy growth while TRVN is negative at -48.92%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-49.98%
Negative yoy SBC while TRVN is 5.47%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
93.54%
Slight usage while TRVN is negative at -1168.73%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
48.23%
AP growth of 48.23% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
21.18%
Some yoy usage while TRVN is negative at -1168.73%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-49.98%
Both negative yoy, with TRVN at -0.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
33.57%
Some CFO growth while TRVN is negative at -16.61%. John Neff would note a short-term liquidity lead over the competitor.
-2609.70%
Negative yoy CapEx while TRVN is 39.73%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2609.70%
Both yoy lines negative, with TRVN at -891.95%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
5.36%
We repay more while TRVN is negative at -1.73%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-80.40%
Negative yoy issuance while TRVN is 357.30%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.